PALVELLA THERAPEUTICS, INC. 8-K

What Happened

• Palvella Therapeutics announced on April 13, 2026 that its Board increased from six to seven members and appointed John Doux, M.D., as a Class III director. Dr. Doux’s initial term expires at the Company’s 2026 Annual Meeting of Stockholders.

Key Details

• Board change effective: April 13, 2026; board size increased from 6 to 7.
• New director: John Doux, M.D., age 57 — board-certified dermatologist, healthcare analyst at Palo Alto Investors since 2004, prior Palvella board member from 2019–2022.
• Compensation: granted an option to purchase 6,000 shares of common stock, vesting in equal monthly installments over 36 months; will receive the standard non-employee director retainer per company policy.
• Governance: No related-party transactions reported; Board determined Dr. Doux is independent under Nasdaq rules.

Why It Matters

• The appointment adds dermatology and healthcare-investing experience to Palvella’s board, and restores continuity given Dr. Doux’s prior service on the company’s board before its reverse merger.
• The option grant is modest (6,000 shares) and standard for non-employee directors; investors should note the governance update and independence determination but there are no disclosed related-party conflicts.